Advice

following a full submission:

trastuzumab emtansine (Kadcyla®) is accepted for use within NHSScotland.

Indication under review: As a single agent, for the adjuvant treatment of adult patients with human epidermal growth factor-2 (HER2) positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2 targeted therapy.

Trastuzumab emtansine was associated with a statistically significant improvement in invasive disease-free survival compared with a HER2 targeted agent in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after completion of neoadjuvant treatment containing a HER2 targeted agent.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
trastuzumab emtansine (Kadcyla)
SMC ID:
SMC2298
Indication:

As a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and / or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
09 November 2020